Drug Type CAR-NK |
Synonyms |
Target |
Mechanism BCMA inhibitors(B-cell maturation protein inhibitors), GPRC5D inhibitors(G-protein coupled receptor family C group 5member D inhibitors), NKG2D antagonists(NKG2-D type II integral membrane protein antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple Myeloma | Preclinical | US | 01 Nov 2024 | |
Myeloid Leukemia | Preclinical | US | - |